Purpose: The purpose of this study was to explore whether there were gender differences in the relation of insulin resistance and β-cell dysfunction to diabetic retinopathy among type 2 diabetic patients. Methods: From 1999 to 2002, a screening regimen for diabetic retinopathy was performed by a panel of ophthalmologists using ophthalmoscopy and 45-degree color fundus photography to examine the fundus in a total of 971 type 2 diabetic patients examined between 1991 and 1993 in Kinmen, Taiwan. Seven hundred and twenty-five type 2 diabetic patients (301 males and 424 females) attended ophthalmological fundus checkup. Results: The response rate in males and females was 71.3 and 77.2%. The proportion of diabetic retinopathy at the first eye screening was 16.3% in males and 20.1% in females. From the multiple logistic regression, the type of diabetes (known cases vs. new cases) was a significant factor of diabetic retinopathy in both males (OR = 3.65, 95% CI: 1.59–8.37) and females (OR = 3.66, 95% CI: 2.01–6.70). Diabetic retinopathy was also strongly affected by the homeostasis model assessment of insulin resistance (HOMA IR) and homeostasis model assessment of β-cell dysfunction (HOMA β-cell) (p < 0.0001 for trend test). In males, those who were in the 2nd quartile, 3rd quartile, and 4th quartile of HOMA IR had 4.87 times (95% CI: 1.18–20.11), 6.83 times (95% CI: 1.91–24.46), and 10.15 times (95% CI: 2.42–42.56) the risk for diabetic retinopathy as compared to those in the 1st quartile. There was a reduced risk for diabetic retinopathy in relation to HOMA β-cell for the 2nd quartile, 3rd quartile, and 4th quartile of 86% (95% CI: 37–97%), 95% (95% CI: 77–99%), and 96% (95% CI: 78–99%) as compared to that in the 1st quartile. Only the 4th quartile had a significant risk (OR = 2.62, 95% CI: 1.17–5.86) for diabetic retinopathy as compared to that in the 1st quartile in females. The reduced risk for diabetic retinopathy found in relation to HOMA β-cell for the 3rd and 4th quartiles were 66% (95% CI: 6–88%) and 66% (95% CI: 10–87%) as compared to that in the 1st quartile. Conclusions: Gender differences in the relationship between insulin resistance/β-cell dysfunction and diabetic retinopathy were demonstrated in type 2 diabetic patients.

Keywords:
Type 2 diabetes, Diabetic retinopathy, Insulin resistance, β-Cell dysfunction
1.
Ciulla TA, Amador AG, Ziman B: Diabetic retinopathy and diabetic macular edema. Diabetes Care 2003;26:2653–2664.
2.
Kohner EM, Aldington SJ, Stratton IM, et al: United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol 1998;116:297–303.
3.
Dowse GK, Humphrey AR, Collins VR, et al: Prevalence and risk factors for diabetic retinopathy in the multiethnic population of Mauritius. Am J Epidemiol 1998;147:448–457.
4.
Haddad OA, Saad MK: Prevalence and risk factors for diabetic retinopathy among Omani diabetics. Br J Ophthalmol 1998;82:901–906.
5.
Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL: The Wisconsin epidemiologic study of diabetic retinopathy. 3. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984;102:527–532.
6.
UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703–713.
7.
Chen MS, Kao CS, Fu CC, Chen CJ, Tai TY: Prevalence and risk factors of diabetic retinopathy among non-insulin-dependent diabetic subjects. Am J Ophthalmol 1992;114:723–730.
8.
LeRoith D: Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med 2002;113(suppl 6A):3S–11S.
9.
Wallace TM, Matthews DR: The assessment of insulin resistance in man. Diabetes Med 2002;19:527–534.
10.
Ferrannini E: Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus. Problems and prospects. Endocr Rev 1998;19:477–490.
11.
Haffner SM, D’Agostino RB, Saad MF, et al: Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites – The Insulin Resistance Atherosclerosis Study. Diabetes 1996;45:742–748.
12.
Li CL, Tsai ST, Chou P: Relative role of insulin resistance and β-cell dysfunction in the progression to type 2 diabetes – The Kinmen Study. Diabetes Res Clin Pract 2003;59:225–232.
13.
Suzuki K, Watanabe K, Motegi T, Kajinuma H: High prevalence of proliferative retinopathy in diabetic patients with low pancreatic β-cell capacity. Diabetes Res Clin Pract 1989;6:45–52.
14.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
15.
Chou P, Liao MJ, Kuo HS, Hsiao KJ, Tsai ST: A population survey on the prevalence of diabetes in Kin-Hu, Kinmen. Diabetes Care 1994;17:1055–1058.
16.
World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. 1. Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Organization, 1999.
17.
Emoto M, Nishizawa Y, Maekawa K, et al: Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 1999;157:836–848.
18.
Bonora E, Targher G, Alberiche M, et al: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57–63.
19.
Wilkinson CP, Ferris FL 3rd, Klein RE, et al: Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003;110:1677–1682.
20.
Katsumori K, Wasada T, Kuroki H, et al: Prevalence of macro- and microvascular diseases in non-insulin-dependent diabetic and borderline glucose-intolerant subjects with insulin resistance syndrome. Diabetes Res Clin Pract 1995;29:195–201.
21.
Maneschi F, Mashiter K, Kohner EM: Insulin resistance and insulin deficiency in diabetic retinopathy of non-insulin-dependent diabetes. Diabetes 1983;32:82–87.
22.
Madsbad S, Lauritzen E, Faber OK, Binder C: The effect of residual beta-cell function on the development of diabetic retinopathy. Diabet Med 1986;3:42–45.
23.
Kuusisto J, Lempiainen P, Mykkanen L, Laakso M: Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men. Diabetes Care 2001;24:1629–1633.
24.
Pyorala M, Miettinen H, Halonen P, Laakso M, Pyorala K: Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 2000;20:538–544.
25.
Lempiainen P, Mykkanen L, Pyorala K, Laakso M, Kuusisto J: Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999;100:123–128.
26.
Schiffrin A, Suissa S, Weitzner G, Poussier P, Lalla D: Factors predicting course of β-cell function in IDDM. Diabetes Care 1992;15:997–1001.
27.
Livingstone C, Collison M: Sex steroids and insulin resistance. Clin Sci 2002;102:151–166.
28.
Ciulla TA, Amador AG, Zinman B: Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003;26:2653–2664.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.